Annual Secretarial Compliance Report for the FY year ended 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Practicing Company Secretary Kala Agarwal has certified Fredun Pharmaceuticals' compliance with SEBI regulations for FY 2024-25. No new deviations or non-compliances were observed during the current review period. The report confirms compliance with Secretarial Standards, board policies, website disclosures, director eligibility, related party transactions, insider trading rules, and timely event disclosures. No actions were taken by SEBI or stock exchanges against the company during the year. The report also tracks resolutions of seven previous compliance issues from FY 2023-24, all related to delays in appointing an Independent Director after Mr. Chandrakant Shah's resignation in July 2023, for which total fines of approximately Rs. 4.67 lakh were paid, and delays in warrant conversion trading approvals (10,000 and 5,000 warrants). All prior issues have since been remediated.
Positive for shareholders — the company has a clean compliance record for the current year and has resolved all historical lapses. With a peer-reviewed auditor and properly constituted board committees now in place, governance risk has been reduced. No new regulatory action or penalties to worry about.